ANIMI-3 WITH VITAMIN D — folic acid, cholecalciferol, pyridoxine hydrochloride, cyanocobalamin, omega-3 fatty acids, doconexent, icosapent and soy sterol capsule
PBM Pharmaceuticals, Inc
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
Animi-3® with Vitamin D
Each Capsule Contains:
Folic Acid (Vitamin B9) 1mg
Cholecalciferol (Vitamin D3) 1000IU
Pyridoxine Hydrochloride (Vitamin B6) 12.5mg
Cyanocobalamin (Vitamin B12) 500mcg
Omega-3 Acids 500mg
-Docosahexaenoic Acid (DHA) 350mg
-Eicosapentaenoic Acid (EPA) 35mg
Phytosterols (Plant Sterols) 200mg
Animi-3® with Vitamin D Capsules are intended for oral administration.
Each Capsule Contains: 1mg Vitamin B-9 (Folic Acid USP), 1000IU Vitamin D-3 (Cholecalciferol), 12.5mg Vitamin B-6 (Pyridoxine Hydrochloride, USP), 500mcg vitamin B-12 (Cyanocobalamin, USP), Pharmaceutical Grade omega-3 Fish Oil providing 500mg Omega-3 Acids; including 350mg Docosahexaenoic Acid (DHA) and 35mg Eicosapentaenoic Acid (EPA) and 200mg Plant Sterols (Phytosterols).
Also Contains: Bleached Lecithin NF, Ascorbic Acid USP, Mixed Tocopherols NF, Ascorbyl Palmitate NF and a soft shell capsule (which contains; Gelatin USP, Glycerin NF, Titanium Dioxide USP, FD and C Red #40, FD and C Yellow #6 and USP Purified Water).
Animi-3® with Vitamin D Capsules are indicated for improving nutritional status in conditions requiring Essential Fatty Acids, Vitamin B12, Vitamin B6, Vitamin D3 and Folic Acid supplementation.
This product is contraindicated in patients with a known hyper-sensitivity to any of the ingredients.
Ingestion of more than 3 grams of omega-3 fatty acids per day has been shown to have potential antithrombotic effects, including an increased bleeding time and INR. Administration of omega-3 fatty acids should be avoided in patients on anti-coagulants and in those known to have inherited or acquired bleeding diathesis.
Folic Acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 1.0mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive.
Safety and effectiveness in pediatric patients have not been established.
Pregnancy and Lactation
The safety of phytosterols has not been studied in pregnant or breastfeeding women. There is no evidence that dietary intakes of naturally occurring phytosterols, such as those consumed by vegetarian women, adversely affects pregnancy or lactation.
Adverse Reactions to Animi-3 with Vitamin D
Allergic sensitization has been reported following oral, enteral and parenteral administration of folic acid.
Adults – One capsule per day or as directed by a physician.
Animi-3® with Vitamin D supplied as orange opaque oblong capsules. Each capsule in imprinted with “Animi-3D” in black opacode. Animi-3® with Vitamin D Capsules are available in bottles of 60 capsules (NDC 66213-542-60).
Keep out of reach of children.
Dispense in a well-closed, tight light-resistant container as defined in the USP using a child-resistant closure.
Store at 20-25°C (68-77°F). See USP Controlled Room Temperature. Protect from light and moisture.
PBM Pharmaceuticals, Inc.
Charlottesville, VA 22902
©2011 All Rights Reserved.
NDC 66213-542-60 60 Capsules
Animi 3D with Vitamin D
Folic Acid (Vitamin B-9) 1 mg
Cholecalciferol (Vitamin D-3) 1000 IU
Pyridoxine Hydrochloride (Vitamin B-6) 12.5 mg
Cyanocobalamin (Vitamin B-12) 500 mcg
Omega 3 Acids 500 mg
– Docosahexaenoic Acid (DHA) 350 mg
– Eicosapentaenoic Acid (EPA) 35 mg
Phytosterols (Plant Sterols) 200 mgRx Only
|ANIMI-3 WITH VITAMIN D folic acid, cholecalciferol, pyridoxine hydrochloride, cyanocobalamin, omega-3 fatty acids, doconexent, icosapent capsule|
|Labeler — PBM Pharmaceuticals, Inc (785470050)|
|International Vitamin Corporation||964464114||manufacture|
Revised: 05/2011 PBM Pharmaceuticals, Inc
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.